Invesco Perpetual's Mark Barnett talks about the key stocks driving his funds, the appeal of non-traditional financial companies, and why he remains committed to the pharmaceuticals sector, despite selling GlaxoSmithKline last year.
Following the implementation of pensions freedoms in 2015, income products have been more in demand than ever and one of the go-to groups in this area remains Invesco Perpetual. Despite a high-profile manager change in 2014, when Neil Woodford left to set up his own firm, Invesco Perpetual has managed to retain a large chunk of those assets, which now come under the responsibility of Mark Barnett. The manager runs the largest actively-managed UK equity vehicle, the £12.6bn High Income fund, as well as the £6.5bn Income fund and a number of other vehicles. Having worked at Invesco P...
To continue reading this article...
Join Investment Week for free
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes